Polycystic Ovary Syndrome and BETATROPHIN
Can the Betatrophin be a Reliable Marker of Insulin Resistance in Normal Weight and Overweight Women With Polycystic Ovary Syndrome?
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Introduction: Betatrophin is a protein hormone which has a significant role in glucose homeostasis and lipid metabolism. The aim of this study is to compare the levels of serum betatrophin in overweight and normal weight women with PCOS.
Material and Method: Thirty-five patients normal weight women with PCOS (BMI<25) and 38 obese women with PCOS (BMI≥25) were included in this prospective, cross-sectional study. Patients were selected according to Rotterdam criteria. Serum betatrophin levels were studied by ELISA method and then compared between these two groups besides the following additional parameters as waist circumference/hip circumference ratio, fasting blood glucose, 75 g OGTT (oral glucose tolerance test) results and HOMA-IR levels.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Kayseri
-
Kocasinan, Kayseri, Turkey, 38090
- Kayseri Doğumevi
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
-Polycystic ovary syndrome according to 2003 Rotterdam PCOS Consensus diagnostic criteria
Exclusion criteria
- pregnancy,
- an additional systemic disease (i.e.,hyperprolactinemia, thyroid dysfunction, liver or kidney diseases, cardiovascular disease, hyperlipidemia, type 1 or type 2 diabetes, chronic or acute infection within the previous 30 days),
- morbid obesity,
- smoking,
- the use of medications for contraception, androgen excess, hypertension, hyperglycemia or dyslipidemia at least 3 months before the study.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Group 1 (normal weight with PCOS )
35 cases
|
two groups comparisons
|
|
overweight PCOS
38 cases
|
two groups comparisons
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
serum Betatrophin levels
Time Frame: 30 min
|
ng/L
|
30 min
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
BMI (body mass index)
Time Frame: 5 minute
|
kg/m2
|
5 minute
|
|
Waist/hip ratio
Time Frame: 5 min
|
centimeter
|
5 min
|
|
75 gr OGTT(oral glucose tolerance test)
Time Frame: 2 hours
|
(mg/dl)
|
2 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- EZTB24
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
NCT06671119RecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical Conditions
-
NCT05938335Not yet recruiting
-
NCT02645422Enrolling by invitation
-
NCT04780828CompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, Visceral
-
NCT03843424CompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood
-
NCT03203161Not yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric Surgery
-
NCT03219658Completed
-
NCT03899311Completed
-
NCT06734312RecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation Techniques
-
NCT04698135CompletedMorbid Obesity | Metabolically Healthy Obesity
Clinical Trials on serum marker levels
-
NCT05098691CompletedPre-Eclampsia | Oxidative Stress | Early Onset Preeclampsia | Immunologic Diseases in Pregnancy
-
NCT03041480CompletedChronic Periodontitis (Disorder)
-
NCT01572194TerminatedRenal Failure | Cystic Fibrosis | Lung Transplantation
-
NCT07147335RecruitingCirrhosis | Hepotacellular Carcinoma
-
NCT06091592CompletedColo-rectal Cancer
-
NCT05205707CompletedCOVID-19 | COVID-19 Respiratory Infection
-
NCT03455387CompletedEclampsia | Pre-Eclampsia | HELLP Syndrome | Fetal Death | Placental Abruption | Fetal Growth Retardation, Antenatal
-
NCT07480993CompletedInsulin Resistance | Polycystic Ovary Syndrome (PCOS) | Body Mass Index (BMI) | Betatrophin
-
NCT06229899Completed